{
    "nctId": "NCT05761470",
    "briefTitle": "Neoadjuvant Camrelizumab and Fluzoparib and Nab-paclitaxel in Early Breast Cancer With HRR Gene Mutation",
    "officialTitle": "A Phase II Study of Camrelizumab, Fluzoparib and Nab-paclitaxel in Neoadjuvant Therapy of Her-2 Negative Breast Cancer Patients With HRR Gene Mutation",
    "overallStatus": "RECRUITING",
    "conditions": "Her-2 Negative Breast Cancer, HRR Gene Mutation",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 66,
    "primaryOutcomeMeasure": "Pathologic Complete Response (pCR)",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Histologically documented Her-2 negative\n* TNM stage: T1c, N1-N2\uff1bT2-4, N0-N2\uff1bany T, N3\n* No distant metastatic disease\n* Eastern Cooperative Oncology Group Performance Status: 0\\~1\n* HRR gene mutation: at least one pathogenic or likely pathogenic variant in germline or somatic BRCA1, BCRA2 and PALB2 genes, or in germline ATM, BARD1, BRIP1, CDK12, CHEK2, RAD51C, RAD51D genes.\n\nExclusion Criteria:\n\n* Patients who are pregnant or lactating at the time of randomization or refuse to contraception.\n* Patients who have other malignant diseases within 2 years, except for cured skin basal cell carcinoma, breast carcinoma in situ or cervical carcinoma in situ\n* Patients with psychiatric disorder, peripheral or central nerve system disease or any disorder, which compromises ability to give informed consent or participate in this study.\n* Patients who have myocardial infarction or congestive heart failure, or other serious cardiac disease.\n* Patients who have used immunosuppressive drug or corticosteroids within 14 days.\n* Patients who have other diseases which researchers.\n* Patients who allergy to any of the drugs in this trail.",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}